
==== Front
World J Diabetes
WJD
World Journal of Diabetes
1948-9358
Baishideng Publishing Group Inc

jWJD.v15.i9.pg1829
10.4239/wjd.v15.i9.1829
90950
Editorial
Exploring the genetic basis of childhood monogenic diabetes
Sanyal D. Genetics of childhood monogenic diabetes
Sanyal Debmalya Department of Endocrinology, KPC Medical College, Kolkata Pin 700032, West Bengal, India
Department of Endocrinology, NH RTIICS, Kolkata Pin 700099, West Bengal, India
School of Medicine, University of New Castle, Callaghan NSW 2308, Australia. drdebmalyasanyal@gmail.com

Author contributions: Sanyal D contributed to manuscript development.

Corresponding author: Debmalya Sanyal, FACE, FRCP, MBBS, MD, MRCP, Professor, Department of Endocrinology, KPC Medical College, 1F Raja Subodh Chandra Mullick Road, Kolkata Pin 700032, West Bengal, India. drdebmalyasanyal@gmail.com

15 9 2024
15 9 2024
15 9 18291832
18 12 2023
29 5 2024
28 6 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Monogenic diabetes is caused by one or even more genetic variations, which may be uncommon yet have a significant influence and cause diabetes at an early age. Monogenic diabetes affects 1% to 5% of children, and early detection and genetically focused treatment of neonatal diabetes and maturity-onset diabetes of the young can significantly improve long-term health and well-being. The etiology of monogenic diabetes in childhood is primarily attributed to genetic variations affecting the regulatory genes responsible for beta-cell activity. In rare instances, mutations leading to severe insulin resistance can also result in the development of diabetes. Individuals diagnosed with specific types of monogenic diabetes, which are commonly found, can transition from insulin therapy to sulfonylureas, provided they maintain consistent regulation of their blood glucose levels. Scientists have successfully devised materials and methodologies to distinguish individuals with type 1 or 2 diabetes from those more prone to monogenic diabetes. Genetic screening with appropriate findings and interpretations is essential to establish a prognosis and to guide the choice of therapies and management of these interrelated ailments. This review aims to design a comprehensive literature summarizing genetic insights into monogenetic diabetes in children and adolescents as well as summarizing their diagnosis and management.

Monogenic diabetes
Genetic mutation
Insulin resistance
Beta-cell function
Diabetes mellitus
==== Body
pmc Core Tip: Monogenic diabetes, a rare yet impactful condition in childhood, results from genetic variations, causing early-onset diabetes. Affecting 1%-5% of children, early detection and tailored genetic treatments can enhance long-term health. Culprits include genetic variations in beta-cell regulatory genes and severe insulin resistance. Identifying specific types allows transitioning to sulfonylureas while maintaining glucose control. Tools to differentiate diabetes types underscore genetic screening's importance for prognosis and treatment guidance. This review delves into genetic insights into childhood monogenic diabetes, offering diagnosis and management guidance for affected youth's better health.

INTRODUCTION

In the ever-evolving landscape of pediatric healthcare, the intricate interplay between genetics and clinical outcomes becomes a central focus of research and treatment strategies. This review article by Sun and Lin[1] delves into the complex world of childhood monogenic diabetes, seamlessly connecting genetic mutations, clinical manifestations, and innovative management approaches. This comprehensive review serves as a beacon, illuminating the path toward improved understanding and personalized care for young patients grappling with this condition.

GENETICS OF CHILDHOOD MONOGENIC DIABETES

Diabetes mellitus (DM) is a metabolic disorder associated with increased blood glucose levels and its associated symptoms which significantly impact an individual’s health, life expectancy, and public health. The lifetime risk of DM is one in three for individuals born in the United States[2]. This multifaceted condition includes autoimmune-mediated type 1 diabetes, injury-induced diabetes, genetically influenced diabetes, and the prevalent type 2 diabetes[3,4]. This article focuses on monogenic diabetes, a less common but genetically distinct form, accounting for about 1% to 5% of cases in pediatric and young populations[5-7].

Monogenic diabetes arises from mutations in a single gene, representing a distinct subset that lends itself to more targeted therapies. There are several forms of monogenic diabetes including maternally inherited diabetes and deafness, gestational diabetes due to the glucokinase (GCK) gene and maturity-onset diabetes of the young (MODY)[8-10]. Despite its lower prevalence (1%-5% in pediatric and young populations), accurate diagnosis remains a challenge, with approximately 80% of cases undetected[7].

Sun and Lin[1] explore the variation in genes linked to childhood diabetes, particularly focusing on ATP-sensitive potassium channels. These genes, like KCNJ11 and ABCC8, play a crucial role in forming KATP channels. The article discusses how these gene variations impact insulin release and the importance of catching them early, opening up possibilities for moving away from insulin reliance to oral medications.

Monogenic diabetes offers a unique window into diabetes pathophysiology, with genetic variations serving as key players. While comprising a small percentage of overall diabetes cases, the well-defined genetic basis allows for precise prognostic and treatment procedures. However, due to its clinical and genetic heterogeneity, diagnosing monogenic diabetes, especially in pediatric patients, remains challenging[11].

The review unfolds the hidden mechanism within the INS and GCK genes, revealing their role in causing permanent neonatal diabetes. By focusing on disruptions caused by INS mutations and the contribution of GCK mutations to familial hyperglycemia, Sun and Lin stress the need for early diagnosis, especially in couples with close family ties. This decoding sets the stage for more effective treatments and understanding familial risks.

The narrative extends to rare genetic origins and variations in childhood diabetes. Sun and Lin[1] shed light on clinical landscapes, underlining the importance of accurate diagnoses in conditions like Wolfram syndrome. This review emphasizes the diversity within childhood diabetes, urging doctors to be vigilant in how they diagnose.

Recent progress in genetic testing, particularly through next-generation sequencing (NGS) technologies, has significantly enhanced the identification of specific genetic mutations linked to monogenic diabetes. NGS enables a more thorough genetic analysis, unveiling rare mutations that traditional methods might overlook. Machine learning algorithms are also emerging to assist in interpreting genetic data, streamlining the diagnostic process[12-14]. Therapeutically, the article talks about personalized treatment plans, especially using sulfonylureas for specific gene mutations like HNF1A-MODY3, showing how genetic insights can guide more effective treatment choices. The review provides valuable insights, but its relevance might vary due to regional genetic differences, and some recent advancements or lesser-known mutations may not be fully addressed, affecting how it can be applied and accessed equitably.

Tailoring treatment for monogenic diabetes is evolving, guided by a deeper understanding of the genetic basis. Gene-based therapies, including CRISPR-Cas9 gene editing, show promise in correcting genetic mutations responsible for monogenic diabetes subtypes. Initiatives including international collaborations and data-sharing could further enhance treatment strategies and outcomes[15-17].

CONCLUSION

The collaborative work of Sun and Lin[1] navigates a genetic exploration in pediatric diabetes. Their comprehensive review not only enhances our understanding of the intricate genetic tapestry but also paves the way for a future where personalized care becomes the cornerstone of pediatric diabetes management.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Endocrinology and metabolism

Country of origin: India

Peer-review report’s classification

Scientific Quality: Grade C, Grade C

Novelty: Grade B, Grade B

Creativity or Innovation: Grade B, Grade C

Scientific Significance: Grade B, Grade B

P-Reviewer: Soriano-Ursúa MA S-Editor: Li L L-Editor: A P-Editor: Zhang YL
==== Refs
1 Sun HY Lin XY Genetic perspectives on childhood monogenic diabetes: Diagnosis, management, and future directions World J Diabetes 2023 14 1738 1753 38222792
2 Yoshiji S Horikawa Y Kubota S Enya M Iwasaki Y Keidai Y Aizawa-Abe M Iwasaki K Honjo S Hosomichi K Yabe D Hamasaki A First Japanese Family With PDX1-MODY (MODY4): A Novel PDX1 Frameshift Mutation, Clinical Characteristics, and Implications J Endocr Soc 2022 6 bvab159 34988346
3 Aydogan HY Gul N Demirci DK Mutlu U Gulfidan G Arga KY Ozder A Camli AA Tutuncu Y Ozturk O Cacina C Darendeliler F Poyrazoglu S Satman I Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients OMICS 2022 26 218 235 35333605
4 Murphy R Colclough K Pollin TI Ikle JM Svalastoga P Maloney KA Saint-Martin C Molnes J ADA/EASD Precision Medicine Diabetes Initiative, Misra S, Aukrust I, de Franco A, Flanagan SE, Njølstad PR, Billings LK, Owen KR, Gloyn AL A Systematic Review of the use of Precision Diagnostics in Monogenic Diabetes medRxiv 2023
5 Rodrigues KF Yong WTL Bhuiyan MSA Siddiquee S Shah MD Venmathi Maran BA Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review Biology (Basel) 2022 11
6 Thomas CC Philipson LH Update on diabetes classification Med Clin North Am 2015 99 1 16 25456640
7 American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020 Diabetes Care 2020 43 S14 S31 31862745
8 Riddle MC Philipson LH Rich SS Carlsson A Franks PW Greeley SAW Nolan JJ Pearson ER Zeitler PS Hattersley AT Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors' Expert Forum Diabetes Care 2020 43 3117 3128 33560999
9 Shepherd M Shields B Hammersley S Hudson M McDonald TJ Colclough K Oram RA Knight B Hyde C Cox J Mallam K Moudiotis C Smith R Fraser B Robertson S Greene S Ellard S Pearson ER Hattersley AT UNITED Team Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes Diabetes Care 2016 39 1879 1888 27271189
10 Hattersley AT Patel KA Precision diabetes: learning from monogenic diabetes Diabetologia 2017 60 769 777 28314945
11 Sanyoura M Philipson LH Naylor R Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options Curr Diab Rep 2018 18 58 29931562
12 Nasykhova YA Barbitoff YA Serebryakova EA Katserov DS Glotov AS Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes World J Diabetes 2019 10 376 395 31363385
13 Vora LK Gholap AD Jetha K Thakur RRS Solanki HK Chavda VP Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design Pharmaceutics 2023 15
14 Yang Y Chen S Liu Y Huang Y Cheong KL Teng B Liu W Long-term treatment of polysaccharides-based hydrogel microparticles as oral insulin delivery in streptozotocin-induced type 2 diabetic mice Biomed Pharmacother 2021 133 110941 33232923
15 Pillon NJ Loos RJF Marshall SM Zierath JR Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care Cell 2021 184 1530 1544 33675692
16 Sweeting A Wong J Murphy HR Ross GP A Clinical Update on Gestational Diabetes Mellitus Endocr Rev 2022 43 763 793 35041752
17 Kotagama OW Jayasinghe CD Abeysinghe T Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases Biomed Res Int 2019 2019 1369682 31687377
